Please click here to obtain permission to reproduce this image.
Click on image to view larger version.
Figure 2 Time to Benefit According to KIF6 719Arg Carrier Status
Hazard ratio for death or major cardiovascular events at 30, 90, and 180 days, 2 years, and at the end of follow-up. High-dose atorvastatin therapy was compared with standard-dose pravastatin therapy according to KIF6 719Arg carrier status. The cumulative incidence of death or major cardiovascular events was estimated by the Kaplan-Meier method. CI = confidence interval.
|
